JY BioMed Showcases Advances in Cell Therapy, Antibody Engineering, and Exosome Research at the 2025 Healthcare+ Expo Taiwan

Taipei, Taiwan – December 7, 2025 — JY BioMed (集研生醫股份有限公司) , a biotechnology company dedicated to advancing next-generation immunology and regenerative science, announced the successful presentation of its latest preclinical research programsat the 2025 Healthcare+ Expo Taiwan, held from December 4–7 at the Taipei Nangang Exhibition Center.

The Healthcare+ Expo Taiwan is one of Asia’s leading biomedical innovation events, gathering global experts from biotechnology, clinical medicine, and digital health. JY BioMed participated in this year’s exhibition to present scientific progress across three key research platforms: gamma-delta T cells, mesenchymal stem cell–derived exosomes, and a humanized heavy-chain antibody–drug conjugate (HCAb-ADC) targeting CEACAM6.

Preclinical Research Highlights Presented at the Expo

1. Unmodified Gamma-Delta T Cells for Cancer Immunology

   JY BioMed presented new data exploring the biological characteristics of unmodified γδ T cells, including dose-dependent responses in tumor models, immune phenotyping, and early-stage safety observations in vitro and in vivo.

   These investigations remain in the preclinical research phase and contribute to the scientific understanding of allogeneic γδ T-cell platforms.

2. Mesenchymal Stem Cell–Derived Exosomes in Neurodegenerative Disease Research

   Another poster highlighted the company’s exploratory studies evaluating biodistribution, behavioral assessments, and tolerability of MSC-derived exosomes in neurological models.

   The research focuses on elucidating exosome-mediated biological mechanisms and is not intended to imply clinical efficacy or therapeutic claims.

3. Humanized Heavy-Chain Antibody and ADC Targeting CEACAM6

   JY BioMed introduced a humanized heavy-chain antibody (HCAb) demonstrating specific CEACAM6 binding properties and efficient cellular internalization. The platform is further being evaluated as a potential antibody–drug conjugate (ADC) candidate in multiple preclinical cancer models.

   These findings remain preliminary and support the early translational assessment of HCAb-based therapeutics.

About JY BioMed

JY BioMed is a biotechnology company dedicated to the research, development, and commercialization of cell- and exosome-based therapeutics for oncology, immunology, and regenerative medicine. Our pipeline includes programs in mesenchymal stem cells (MSCs), dendritic cell cancer vaccines, γδ T cells, NK cell therapy, and antibody-drug conjugates (ADCs), supported by partnerships with leading academic and clinical institutions.

Website: www.jy-biomed.com